Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank raised its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 7.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 512,449 shares of the company's stock after acquiring an additional 36,843 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Teva Pharmaceutical Industries were worth $7,876,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in TEVA. Oarsman Capital Inc. purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $29,000. Golden State Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries during the 1st quarter worth $39,000. Marshall & Sterling Wealth Advisors Inc. purchased a new position in Teva Pharmaceutical Industries during the 4th quarter worth $44,000. Compagnie Lombard Odier SCmA purchased a new position in Teva Pharmaceutical Industries during the 1st quarter worth $54,000. Finally, Versant Capital Management Inc raised its holdings in shares of Teva Pharmaceutical Industries by 437.8% in the first quarter. Versant Capital Management Inc now owns 5,297 shares of the company's stock valued at $81,000 after buying an additional 4,312 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on TEVA shares. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $21.00 to $23.00 in a research report on Monday, May 12th. UBS Group decreased their price target on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a report on Thursday, June 26th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective for the company. Finally, Truist Financial assumed coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price for the company. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $24.71.

Teva Pharmaceutical Industries Trading Down 0.5%

TEVA traded down $0.07 during midday trading on Friday, hitting $15.38. The company's stock had a trading volume of 14,134,433 shares, compared to its average volume of 11,701,027. The firm has a market cap of $17.64 billion, a P/E ratio of -96.13, a PEG ratio of 0.91 and a beta of 0.62. The firm has a 50-day moving average price of $16.89 and a two-hundred day moving average price of $16.67. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80. The company has a current ratio of 1.06, a quick ratio of 0.74 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%. The business had revenue of $4.18 billion during the quarter, compared to analysts' expectations of $4.34 billion. During the same quarter in the previous year, the business earned $0.61 EPS. The company's revenue for the quarter was up .3% on a year-over-year basis. On average, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total transaction of $105,626.12. Following the completion of the sale, the executive vice president owned 9,989 shares in the company, valued at $170,012.78. This trade represents a 38.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.49% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.